Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1207-Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.
Application Number1207
Application NameTesting for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies
Description of Medical ServiceBRAF V600 mutation testing for locally advanced unresectable stage III or IV melanoma to determine eligibility for access to dabrafenib (co-dependent technology).
Description of Medical ConditionMelanoma in its advanced form has a poor prognosis. It is increasing in incidence in Australia and globally, and occurs when mutations accumulate in the melanocytes of the skin, mainly as a result of exposure to ultra-violet radiation from sunlight. When mutations accumulate they can eventually deregulate growth and cell cycle control genes, and to lead to tumour formation through proliferation and metastasis of cells.
Protocols12-13 April 2012
PDF version Final Decision Analytic Protocol (PDF 2745 KB)
Word version Final Decision Analytic Protocol (DAP) (Word 1022 KB)
ConsultationDate of released for comment 27 January 2012
PDF version Consultation Decision Analytic Protocol (DAP) (PDF 826 KB)
Word version Consultation Decison Analytic Protocol (DAP) (Word 751 KB)
Date of closed for comments 10 March 2012
Reports-
MSAC OutcomesPDF version Public Summary Document - April 2013 (PDF 85 KB)
Word version Public Summary Document - April 2013 (Word 678 KB)

PDF version Public Summary Document - August 2013 (PDF 80 KB)
Word version Public Summary Document - August 2013 (Word 78 KB)

Meetings for this Application:

Meeting Type:Date:
PASC1 and 2 December 2012
12 and 13 April 2012
ESC 13 and 14 June 2013
MSAC 5 April 2013
1 August 2013

Page currency, Latest update: 20 April, 2015